Compare Indonesia Energy Corporation Limited (INDO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Sanofi SA — how do they compare? Indonesia Energy Corporation Limited trades at $3 (market cap $46.01M), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2278.4× Indonesia Energy Corporation Limited's market cap, and Sanofi SA pays a 5.5% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| INDO | SNY | |
|---|---|---|
Market Cap | $46.01M | $104.83B |
Sector | Energy | Health |
52-Week High | $6.74 | $52.34 |
52-Week Low | $2.49 | $41.33 |
Enterprise Value | $41.38M | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical outlook supported by positive moving averages and ADX signals. The company is in a high-risk growth phase, reporting a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block, which could drive future revenue if successful.
The stock presents speculative upside tied to execution on new oil wells, but carries significant fundamental risk due to current losses and high valuation multiples. Analyst consensus is unanimously bullish, yet investors must weigh potential operational success against the company's fragile financial position and dependence on successful resource extraction.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
